Article
Comparison Between Second- and Third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as First-line Treatment in Patients With Non-small-cell Lung Cancer: A Retrospective Analysis.
Anticancer research - 1 Oct 2021
Mitsuya Sho, Tsuruoka Kenjiro, Kanaoka Kiyoe, Funamoto Tomoya, Tsuji Hiroyuki, Matsunaga Ninso, Nakamura Takahiko, Tamura Yosuke, Imanishi Masafumi, Ikeda Soichiro, Fujisaka Yasuhito, Goto Isao, Imagawa Akihisa
Abstract excerpt
BACKGROUND: For epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), administration of EGFR tyrosine kinase inhibitors (TKIs) is mandatory to prolong survival. To date, a comparison of second- and third-generation EGFR-TKIs has not been reported as far as we are aware. PATIENTS AND METHODS: We retrospectively investigated the survival time of patients diagnosed with EGFR-mutated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.